ClinicaliQ Trial Snapshot
- A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract — Recruiting • Phase III • Oncology • NCT07218380.
- Intervention being tested: Vepugratinib (LY3866288), a novel therapeutic agent, is being evaluated against placebo in a randomised controlled trial to assess safety, tolerability, and efficacy in advanced or metastatic urothelial (bladder) cancer.
- Patient eligibility overview: The trial enrolls adults with advanced or metastatic urothelial cancer; specific eligibility criteria typically include confirmed diagnosis, adequate organ function, and prior treatment history, though detailed inclusion/exclusion criteria would be specified in the full protocol.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
Eligibility Snapshot
- : * Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present. * Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer. * Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 * Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. * Have adequate laboratory parameters
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.